about
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibPYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells.A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Dasatinib first-line: Multicentric Italian experience outside clinical trials.Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.Tyrosine kinase inhibitors and pregnancy.Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature.Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review.Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentOutcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.The impact of dasatinib on pregnancy outcomes.Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation.First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.Management of pregnant chronic myeloid leukemia patients.Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Hodgkin's Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge.High-dose chemotherapy in adult acute myeloid leukemia: rationale and results.Study of clonality in myelodysplastic syndromes: detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization.Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases.Primary pulmonary hodgkin lymphoma simulating a mediastinal tumour: an uncommon occurrence.Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients.Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.Multiple skin tumors in long-term treatment with hydroxyurea.Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
P50
Q29999611-59EB9A8C-3840-4C9B-8E32-28C414A3728AQ30837349-10E88FC5-E00C-4BDE-BC8F-EF52DBBF709EQ31367335-33FCE48B-1FD9-4614-A9E3-012937996387Q33377623-65D266E5-6A40-49D9-82E0-C37A70F47F74Q33384766-02403EFE-BA69-49E0-B7AC-39632E85AC2BQ33428221-BEDCE6B8-22DE-465F-A019-7070B58810DDQ33437121-20A00A50-7841-4D1E-A4E7-F24CCB0887B2Q33441917-3EC072CD-8A40-4782-8E2D-B485068D2196Q33568481-084CF407-A4DE-45C2-A725-13C6821130EBQ33878774-D98B8CE8-70A4-4A0A-975C-12DD09448539Q34808070-28A0BAB7-D68B-4AFB-A769-C865679F7A83Q35130023-377703B4-4954-4C96-A31C-19DD0ACD29F2Q35265868-93D819C1-0AD8-4806-A449-A279562E6876Q36288815-5C923151-49FD-4B84-8FB0-326DF54A7FF7Q36862301-13C65A9B-A75B-4F2E-9CB4-04B650EB27CAQ37273788-52E6F903-0EE8-43F0-885A-69EA5D1D60E0Q37423501-8F94DF53-A24B-49FF-8C13-52D8E1828A46Q38467409-01B31171-2277-4C5C-9C4F-00F27BDD8118Q38620872-67B2D17B-6618-4372-8CAF-C2C68F865C22Q38879793-9E0039ED-2006-45FD-9D64-7CF72BCD4FCDQ38973320-FE25C8FB-91F5-4C39-9A15-500AA54D845AQ39924810-A4E1A5A9-BF03-411F-ADD0-D7EC0E91D053Q40217698-6509E10E-A582-41B5-A199-428C6AA67B59Q40296906-B31D8532-CD96-42F7-B1B3-FFF4E39836C7Q40608260-42A1BD18-AA6B-47DF-8597-E44B346ADC49Q40821920-4EF542AC-B7B5-4E60-A552-9F3CCABE3920Q40980827-7592DA9D-E027-4094-B1B8-AD4ECFDD367EQ41104416-D3B93C76-5ED7-4973-B138-58F40170826CQ41188114-1F4B329B-C2E0-48E5-B9A4-E57C7E577281Q41392348-AF5B1AC3-2E25-4C84-B89F-1AFCF717B3ACQ41478079-027E844C-4E63-44FB-BC61-F5E38481A8F9Q42011392-BD85E963-3A73-4479-B641-41F7C653703CQ42316987-C39F13E7-1840-446B-84E5-C31C6E26C011Q42926639-D58E1875-CD9A-4A92-BACA-0A736DF1C39CQ42939571-7A7DB38B-7D04-4461-B4B0-69E8B5C53111Q43075393-D9AEBD94-2DB8-4A8E-BB81-531551A38863Q43475684-B03D7B0F-06D0-4CE1-B560-4DD9C23D5E50Q43851252-5F7E7B8A-DB4F-4BF8-B741-AA3B85BAB7D0Q44167290-ADAA66D1-22EF-4DC1-90B4-3A8907553762Q44654361-DB929242-FA24-4B49-93D4-1E84A6F4E855
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisabetta Abruzzese
@ast
Elisabetta Abruzzese
@en
Elisabetta Abruzzese
@es
Elisabetta Abruzzese
@nl
Elisabetta Abruzzese
@sl
type
label
Elisabetta Abruzzese
@ast
Elisabetta Abruzzese
@en
Elisabetta Abruzzese
@es
Elisabetta Abruzzese
@nl
Elisabetta Abruzzese
@sl
prefLabel
Elisabetta Abruzzese
@ast
Elisabetta Abruzzese
@en
Elisabetta Abruzzese
@es
Elisabetta Abruzzese
@nl
Elisabetta Abruzzese
@sl
P106
P21
P31
P496
0000-0001-5228-6491